

**Supplemental
Notice of Allowability**

Application No.

10/572,523

Examiner

KAGNEW H. GEBREYESUS

Applicant(s)

BAUER, SHABTAI

Art Unit

1656

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to 5/5/2010.
2. ☒ The allowed claim(s) is/are 1-24 and 41-54.
3. ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some* c) ☐ None of the:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. ____.
3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).
- * Certified copies not received: ____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

4. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
- (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
- 1) ☐ hereto or 2) ☐ to Paper No./Mail Date ____.
- (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date ____.
- Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).**
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

- | | |
|--|---|
| 1. <input type="checkbox"/> Notice of References Cited (PTO-892) | 5. <input type="checkbox"/> Notice of Informal Patent Application |
| 2. <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 6. <input checked="" type="checkbox"/> Interview Summary (PTO-413),
Paper No./Mail Date <u>7/14/2010</u> . |
| 3. <input checked="" type="checkbox"/> Information Disclosure Statements (PTO/SB/08),
Paper No./Mail Date <u>5/5/2010</u> | 7. <input checked="" type="checkbox"/> Examiner's Amendment/Comment |
| 4. <input type="checkbox"/> Examiner's Comment Regarding Requirement for Deposit
of Biological Material | 8. <input checked="" type="checkbox"/> Examiner's Statement of Reasons for Allowance |
| | 9. <input type="checkbox"/> Other ____. |

/Kagnew H Gebreyesus/
Acting Examiner of Art Unit 1656

DETAILED ACTION

This Supplemental Notice of Allowance is being mailed in order to correct the claim dependency of claim 41. Claim 41 has now been amended to depend from claim 1 as opposed to claim 40 which has been cancelled.

Applicant's response on May, 5, 2010 to the Office Action dated February 18, 2010 is acknowledged. Applicants have cancelled claims 25-39. Applicants have amended claim 1 and added new claims 40-54. Thus claims 1-24 and 40-54 are present for examination.

Priority

Acknowledgment is made for the benefit for priority under 35 U.S.C. 119(a)-(d) from foreign application IL158053 filed on 09/22/2003 and provisional application filed under 119 (e) from 60/503,902 also filed on 9/22/2003. The certified copy has been filed in this application.

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Attorney Allan A. Fanucci on July 14, 2010.

Art Unit: 1656

Summary of amendments: The limitation of claim 40 was incorporated in claim 1.

Therefore claim 40 is cancelled. Claims 1-5 and claim 22 were amended. Claims 1-24 and 41-54 are allowed. The amendments are as follows:

EXAMINER'S AMENDMENT

Amend claim 1 as follows:

- Claim 1 (Currently Amended) A large scale process for purifying alpha-1 proteinase inhibitor (API) from an unpurified mixture of proteins comprising:
 - (a) dispersing the unpurified mixture of proteins containing API in an aqueous medium;
 - (b) removing a portion of contaminating lipids and proteins by adding a lipid removal agent to the aqueous dispersion and precipitating the portion of contaminating proteins from said aqueous dispersion;
 - (c) loading an API-containing supernatant of step (b) containing API on a first anion exchange resin with a buffer solution having pH and conductivity such that API is retained on the first anion exchange resin;
 - (d) eluting an API-containing fraction from said first anion exchange resin with a same type of buffer as in step (c) having adjusted pH and conductivity;
 - (e) loading an API-containing fraction of step (d) on a cation exchange resin in said same type of buffer having appropriate pH and conductivity such that API is not retained on the cation exchange resin;
 - (f) collecting a flow-through of step (e) that contains API;
 - (g) loading an API-containing fraction of step (f) on a second anion exchange resin with said same type of buffer having appropriate pH and conductivity such that API binds to the second anion exchange resin; and
 - (h) eluting API from said second anion exchange resin with said same type of buffer having adjusted pH and conductivity to obtain ~~a stable solution containing purified, active API~~ a purified active API which is stable without the addition of a protein stabilizer.

- Claim 2, 3 and 5 delete the recitation of the term “obtained”
- Claim 4 delete the recitation “solution”

- Amend claim 22 and 23 as follows:

22. (Amended) The process of claim 1, further comprising changing the ionic composition of the solution containing the purified, active API to contain a physiologically compatible ion and sterilizing the resulted solution.

23. The process of claim 22, wherein the solution containing API is concentrated before loading on the ion exchange resin.

Cancel claim 40.

Claim 41. (Amended) The process of claim ~~40~~ 1 which further comprises formulating a pharmaceutical preparation comprising the purified active stable API as an active ingredient.

Conclusion: Claims 1-24 and 41-54 are allowed.

REASONS FOR ALLOWANCE

The following is an examiner’s statement of reasons for allowance: Above claims have been allowed based on the applicant’s argument that the above method can be used for large scale purification of API wherein said purified API is highly stable in solution without addition of a protein stabilizer, which was unexpected, comprising purifying the API in an anion exchange resin, a cation exchange resin followed by a second anion exchange resin is not or rendered obvious anticipated by the prior art.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably

Art Unit: 1656

accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to KAGNEW H. GEBREYESUS whose telephone number is (571)272-2937. The examiner can normally be reached on 8:30am-5:30pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, MANJUNATH RAO can be reached on 571-272-0939. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Art Unit: 1656

If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Kagnew H Gebreyesus/
Acting Examiner of Art Unit 1656
July 14, 2010

/Manjunath N. Rao /
Supervisory Patent Examiner, Art Unit 1656